Compare TNYA & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNYA | KZIA |
|---|---|---|
| Founded | 2016 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 181.5M | 154.9M |
| IPO Year | 2021 | 2002 |
| Metric | TNYA | KZIA |
|---|---|---|
| Price | $0.80 | $13.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $5.33 | ★ $19.50 |
| AVG Volume (30 Days) | ★ 2.7M | 163.5K |
| Earning Date | 05-07-2026 | 06-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 54.96 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.53 | $4.86 |
| 52 Week High | $2.35 | $17.40 |
| Indicator | TNYA | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 50.07 | 47.19 |
| Support Level | $0.65 | $11.90 |
| Resistance Level | $0.80 | $14.75 |
| Average True Range (ATR) | 0.07 | 0.99 |
| MACD | 0.00 | -0.10 |
| Stochastic Oscillator | 39.32 | 32.55 |
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.